After several years of relative price stability for US generics companies, following the painful fallout from the most recent cycle in 2016-17 that rocked manufacturers big and small, the thorny issue of pricing pressure began to rear its head again last year.
“A lot of that’s being driven because of volume declines we saw in Q1,” observed Sandoz Inc. head Richard...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?